These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35223402)

  • 1. MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients.
    Tehrani SS; Zaboli E; Sadeghi F; Khafri S; Karimian A; Rafie M; Parsian H
    Biomedicine (Taipei); 2021; 11(2):30-39. PubMed ID: 35223402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
    Ichikawa T; Sato F; Terasawa K; Tsuchiya S; Toi M; Tsujimoto G; Shimizu K
    PLoS One; 2012; 7(2):e31422. PubMed ID: 22384020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN.
    Wang H; Hu Z; Chen L
    Oncol Lett; 2018 Oct; 16(4):4223-4228. PubMed ID: 30197668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression.
    Huang ZM; Ge HF; Yang CC; Cai Y; Chen Z; Tian WZ; Tao JL
    Kaohsiung J Med Sci; 2019 Aug; 35(8):467-473. PubMed ID: 31063232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
    Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
    J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
    Somlo G; Martel CL; Lau SK; Frankel P; Ruel C; Gu L; Hurria A; Chung C; Luu T; Morgan R; Leong L; Koczywas M; McNamara M; Russell CA; Kane SE
    Breast Cancer Res Treat; 2012 Feb; 131(3):899-906. PubMed ID: 22042372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.
    Zuazana B; Luboš P; Renata C
    Klin Onkol; 2018; 31(3):191-199. PubMed ID: 30441972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
    Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA SNHG6 enhances cell proliferation, migration and invasion by regulating miR-26a-5p/MAPK6 in breast cancer.
    Lv P; Qiu X; Gu Y; Yang X; Xu X; Yang Y
    Biomed Pharmacother; 2019 Feb; 110():294-301. PubMed ID: 30522015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
    Shi YF; Lu H; Wang HB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
    Aogi K; Saeki T; Nakamura S; Kashiwaba M; Sato N; Masuda N; Rai Y; Ohno S; Kuroi K; Nishimura R; Miyakoda K; Akiyama F; Kurosumi M; Ikeda T
    Int J Clin Oncol; 2013 Aug; 18(4):598-606. PubMed ID: 22833344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
    Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
    Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.